Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 58,600 shares, a decrease of 52.9% from the January 31st total of 124,500 shares. Currently, 5.5% of the company’s shares are short sold. Based on an average daily volume of 2,240,000 shares, the short-interest ratio is currently 0.0 days.

Institutional Trading of Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Invst LLC raised its position in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 16.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 50,400 shares of the company’s stock after buying an additional 7,200 shares during the quarter. Invst LLC owned about 4.31% of Evaxion Biotech A/S worth $43,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Analysts Set New Price Targets

EVAX has been the topic of a number of research analyst reports. Lake Street Capital cut their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Evaxion Biotech A/S in a research note on Thursday, February 20th.

Evaxion Biotech A/S Stock Down 7.6 %

Shares of EVAX stock traded down $0.16 during mid-day trading on Friday, hitting $1.94. 165,833 shares of the stock traded hands, compared to its average volume of 3,639,702. The stock has a market cap of $2.28 million, a P/E ratio of -1.34 and a beta of -0.28. The stock’s fifty day moving average is $3.40 and its two-hundred day moving average is $9.20. Evaxion Biotech A/S has a 52-week low of $1.89 and a 52-week high of $22.05. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.